About Aristea

The Challenge Posed by Human Errors: 

Unnecessary Drug Development Failures

Sci. Transl. Med. 2, 61rv6 (2010).


Aristea Has Researched Drug Developments to Insure Successes in Drug Developments

The AristeaTM Responds to Covid-19

Aristea Translational Medicine Corp.

  Developing PhenT For

Treatment of Silent Hypoxia in Covid-19 Patients.

Recent research into head injury and Alzheimer’s disease supports the use of PhenT as a treatment for Covid-19 infections. In recently initiated preclinical and anticipated clinical trials, Aristea Translational Medicine Corp. using its new drug PhenT, proposes to mitigate SARS-CoV-2 coronavirus alveolar cell damage in the respiratory system and thereby prevent the Covid-19 disease progression into silent hypoxia.  Not obviously symptomatic and symptomatic Covid-19 patients can have dangerously low, life threatening blood oxygenation levels.  This silent hypoxia can require oxygen administration, intubation to allow machine-controlled respiration of patients and leads to death for some patients.I’m your Services section. Click to edit and tell visitors an overview of the featured services you provide.



SARS-2 coronavirus-induced respiratory system damage resulting in pernicious clinical disease and death represents a significant and growing cause for concern worldwide, and has already been estimated to have become a leading cause of death in SARS-2 coronavirus affected populations. Medical evidence suggests that clinically asymptomatic persons, not obviously ill, may progress to serious compromises of pulmonary function before the seriousness of the pathology becomes clinically evident to affected persons and others about them. 

In normal lung, Surfactant protects the alveoli (the tiny air sacs in the lungs) from collapsing and failing to inflate with inspiration.  In Covid-19, viral damage to alveolar cells lining the air sacs in lung reduces surfactant levels causing increased surface tension for the fluid lining the air sacs. Surfactant is a complex mixture of phospholipids and surfactant proteins that reduce alveolar surface tension and support lung inflation. Due to this often rapid and damaging tissue pathological progression, an intervention against the cascade of pathology is desperately needed.  


PhenT has been shown able to block cell dysfunction and death in cultured cells and in five animal models of head trauma, stroke, Alzheimer’s disease and nerve gas toxicity. In Covid-19 this protection or delay could extend alveolar cellular function and counter the reduction of Surfactant, and thus maintains Surfactant concentrations better able to prevent the increase in surface tension to levels required for alveoli to collapse. From the known pathology from SARS-Cov-2 virus infections the protection of alveoli from programmed cell death can be expected to raise the functioning capacity of the lung to both maintain O2 blood saturation and make available working alveoli sufficient to protect these alveoli and others from overstretching and succumbing to the damage cascade found in progressive SARS-Cov-2 virus infections.   


Company Background

Aristea Translational Medicine Corp. is a Utah small business.  Since its incorporation in 2000, with others located at the National Institute on Aging and at US and UK universities, Aristea has investigated the sources of failures in therapeutic drug developments and methods for overcoming unnecessary failures.  Beginning in 2010, with investigators at National Institute on Aging, NIH, Aristea turned its expertise in drug development to clinical pharmacological research that has led to PhenT and its proposed applications preventing cell death. In head injury, Alzheimer’s disease and now Covid-19, uncontrolled programmed cell death leads to irreversible damage, disabilities, and the death of some patients.  Aristea has patents and patents pending for each application.  Currently, with university collaborators at University of Southern California USA and at University of Exeter in the United Kingdom, a $4,000,000 five year National Institute of Aging grant is supporting clinical trials of PhenT in Alzheimer’s disease.


Contact Aristea

Send AristeaTM a Message

Privacy and Data Policy

We will receive your message as an email and respond if you request a response. We will retain your name and email address for future responses to you or to share new developments at AristeaTM unless you request that we erase your information after viewing and, if needed, replying to your message or email. Your message or email will be automatically deleted from our system after 60 days. We do not aggregate data or release or sell data to any third parties about individuals or groups of individuals who have contacted us. Our website does not use cookies.